News | August 12, 2009

Webcast Shows Use of Impella 2.5 in High-Risk PCI

August 12, 2009 – Abiomed Inc. said a webcast of an Impella 2.5 procedure performed on an 85-year-old man with multivessel disease at Mount Sinai Medical Center, now available and archived on the Abiomed Web site www.abiomed.com.

The webcast was broadcasted live from Mount Sinai Medical Center on July 21, 2009 and presents a successful high-risk percutaneous coronary intervention (PCI) case with Impella 2.5 support, performed by Samir Sharma, M.D., director of the catheterization lab and interventions, and Annapoorna Kini, M.D., associate professor of the cath lab at Mount Sinai Medical Center.

The patient, an 85-year-old male with multivessel disease, had a left ventricular ejection fraction (LVEF) of 20 percent, while normal LVEF typically ranges from 60–65 percent. Impella 2.5 was inserted to maintain left ventricular support and provide hemodynamic stability. “(Impella) gives operators the confidence to achieve good results without worrying about hemodynamic compromise,” said Dr. Sharma during the webcast.

For more information: www.abiomed.com

Related Content

Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
Overlay Init